Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

被引：3
|
作者：
Iyer, Chandrasekar
Li, Binghui
Stewart, Trent R.
Wang, Tao
Capen, Andrew
Cavitt, Rachel
Anderson, Bryan D.
Bocchinfuso, Wayne
Zhao, Gaiying
Rodriguez, Michael J.
Carballares, Santiago
Cooke, Andrew
Bondi, Robert
Burns, Lee
Kelamangalath, Lakshmi
Wallace, Ross
Kolakowski, Gabrielle
Henry, James R.
Si, Chong
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B115
引用
收藏
页数：2
相关论文
共 50 条
  • [31] MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration.
    Ying, Grace
    Auckley, Elizabeth
    Aldakkak, Mohammed
    Thalji, Samih Z.
    Vakili, Parnian
    Grahl, Justin
    Mayer, Bradley
    Shahjehan, Faisal
    Low, Soon Khai
    Evans, Douglas B.
    Christians, Kathleen K.
    Seo, Yongwoo David
    Erickson, Beth
    Hall, William Adrian
    Mcfall, Thomas
    Kurzrock, Razelle
    George, Ben
    Kamgar, Mandana
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 726 - 726
  • [32] Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers
    Xiao, Fei
    Wang, Kailiang
    Wang, Xinjuan
    Li, Huijuan
    Hu, Zhilong
    Ren, Xiaoming
    Huang, Wei
    Feng, Teng
    Yao, Lili
    Lin, Jing
    Li, Chunlai
    Zhang, Zhuanzhuan
    Mei, Liufeng
    Zhu, Xiaotian
    Zhong, Wenge
    Xie, Zhi
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (12) : 1703 - 1716
  • [33] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    Constance King
    Henry Diaz
    Darlene Barnard
    David Barda
    David Clawson
    Wayne Blosser
    Karen Cox
    Sherry Guo
    Mark Marshall
    Investigational New Drugs, 2014, 32 : 213 - 226
  • [34] Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor
    King, Constance
    Diaz, Henry
    Barnard, Darlene
    Barda, David
    Clawson, David
    Blosser, Wayne
    Cox, Karen
    Guo, Sherry
    Marshall, Mark
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 213 - 226
  • [35] RAS(ON) G12D-and Multi-selective inhibitor doublet drives complete responses in combination with anti- PD-1 in a preclinical model of MSS KRAS G12D mutant CRC
    Salmon, Avery J.
    Blaj, Cristina
    Tran, Linh
    Payson, Enrico
    Wig, Philip
    Liang, Rich
    Soto-Perez, Paola
    Morton, Vivian
    Sandoval, Miguel
    Smith, Jacqueline A. M.
    Quintana, Elsa
    CANCER IMMUNOLOGY RESEARCH, 2025, 13 (02)
  • [36] Potent anti-tumor activity of a selective and orally bioavailable reversible covalent CDK12 inhibitor
    Khare, Leena
    Poddutoori, Ramulu
    Mukherjee, Subhendu
    Samiulla, D. S.
    Devaraja, T. S.
    Marappan, Sivapriya
    Nayak, Shilpa
    Sivakumar, Sasirekha
    Kaza, Lakshmi
    Tgore, Suraj
    Dhudashiya, Amit
    Raghavendra, N. R.
    Gunnepalli, Bhargav
    Aravind, A. B.
    Amith, A.
    Charamanna, K. B.
    Antony, Thomas
    Nellore, Kavitha
    Daginakatte, Girish
    Chelur, Shekar
    Giri, Sanjeev
    Ramachandra, Murali
    Samajdar, Susanta
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [37] Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
    Thress, Kenneth
    MacIntyre, Terry
    Wang, Haiyun
    Whitston, Dave
    Liu, Zhong-Ying
    Hoffmann, Ethan
    Wang, Tao
    Brown, Jeffrey L.
    Webster, Kevin
    Omer, Charles
    Zage, Peter E.
    Zeng, Lizhi
    Zweidler-McKay, Patrick A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (07) : 1818 - 1827
  • [38] Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
    Thress, K.
    MacIntyre, T.
    Wang, H.
    Liu, Z. Y.
    Hoffmann, E.
    Wang, T.
    Whitston, D.
    Brown, J. L.
    Webster, K.
    Omer, C.
    EJC SUPPLEMENTS, 2008, 6 (12): : 180 - 180
  • [39] Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide
    Black, Cheryl
    Parsons, James
    Thomas, Anthony
    Drain, Allison P.
    Narayan, Santosh
    Francis, Joshua
    He, Xingyue
    Gupta, Ankit
    Webb, Jessica
    Schmitt, Thomas M.
    Greenberg, Philip D.
    Shapiro, Gary
    Vincent, Loic
    CANCER RESEARCH, 2023, 83 (07)
  • [40] Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor
    Leviten, Dina
    Sierra, Teresa
    Dozier, Ashley
    Boyce, Richard
    Boyle, Bob
    Peterson, Scott
    Vo, Alex C.
    CANCER RESEARCH, 2017, 77
12345